Peter J. Mariani - Jan 25, 2023 Form 4 Insider Report for Axogen, Inc. (AXGN)

Signature
/s/Peter Mariani
Stock symbol
AXGN
Transactions as of
Jan 25, 2023
Transactions value $
-$317,650
Form type
4
Date filed
1/27/2023, 04:53 PM
Previous filing
Dec 29, 2022
Next filing
Feb 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXGN Common Stock Options Exercise $106K +20.9K +49.73% $5.04 63K Jan 25, 2023 Direct
transaction AXGN Common Stock Sale -$214K -20.9K -33.21% $10.23 42.1K Jan 25, 2023 Direct F1, F2
transaction AXGN Common Stock Options Exercise $106K +20.9K +49.73% $5.04 63K Jan 26, 2023 Direct
transaction AXGN Common Stock Sale -$207K -20.9K -33.21% $9.90 42.1K Jan 26, 2023 Direct F1, F3
transaction AXGN Common Stock Options Exercise $106K +20.9K +49.73% $5.04 63K Jan 27, 2023 Direct
transaction AXGN Common Stock Sale -$213K -20.9K -33.21% $10.16 42.1K Jan 27, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXGN Employee Stock Option (right to purchase) Options Exercise $0 -20.9K -16.67% $0.00 105K Jan 25, 2023 Common Stock 20.9K $5.04 Direct F5
transaction AXGN Employee Stock Option (right to purchase) Options Exercise $0 -20.9K -20% $0.00 83.8K Jan 26, 2023 Common Stock 20.9K $5.04 Direct F5
transaction AXGN Employee Stock Option (right to purchase) Options Exercise $0 -20.9K -25% $0.00 62.8K Jan 27, 2023 Common Stock 20.9K $5.04 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan, in order to exercise options that are scheduled to expire on March 1, 2023.
F2 The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.05 to $10.76 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.61 to $10.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.70 to $10.34 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5 All shares of Common Stock underlying the employee stock option were fully vested on March 1, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 1, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.